Targets › DNAJB1
2 programs from 2 companies in 5 trials: 5 Phase 1; Oncology; next expected readout Jan 2027.
Interacts with HSP70 and can stimulate its ATPase activity. Acts also with TTC1 as a chaperone adapter that regulates HSP70-dependent folding process by interacting with the HSP70 amino terminal region. (UniProt, P25685)
Open in Phaseline: the race on DNAJB1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University Hospital Tuebingen | Fusion-VAC-XS15 DNAJB1-PRKACA fusion peptide vaccine with TLR1/2 agonist | DNAJB1, PRKACA | Phase 1 | Fibrolamellar Hepatocellular Carcinoma; Fibrolamellar Hepatocellular Carcinoma (FLC) | Jan 2027 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | DNAJB1-PRKACA Peptide Vaccine Peptide vaccine targeting DNAJB1-PRKACA fusion kinase | DNAJB1, PRKACA | Phase 1 | NSCLC Stage IV; Fibrolamellar Hepatocellular Carcinoma (FLC); Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC)) | Jul 2027 |
Fibrolamellar Hepatocellular Carcinoma (FLC) (2) NSCLC Stage IV (1) Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC)) (1) Fibrolamellar Hepatocellular Carcinoma (1)
mixed (1), other (1)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) University Hospital Tuebingen (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.